NCT01649284Approved For MarketingNot Applicable
LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Approved For Marketing
- Sponsor
- Boehringer Ingelheim
- Locations
- 66
Study Overview
Brief Summary
This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (66)
Loading locations...
Similar Trials
No Longer Available
Not Applicable
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNon-Small Cell Lung CancerNCT02271139Genentech, Inc.
Completed
Phase 3
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR MutationCarcinoma, Non-Small-Cell LungNCT01953913Boehringer Ingelheim542
Approved For Marketing
Not Applicable
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryMetastatic Breast CancerNCT01240421Eisai Inc.
Approved For Marketing
Not Applicable
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT01931306Boehringer Ingelheim
Approved For Marketing
Not Applicable
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.